|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Dopamine D2 receptor agonist, Ropinirole, has been found to promote neuroprotection in Parkinson´s disease and restless leg syndrome.
|
31816341 |
2020 |
|
Parkinson Disease
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
DRD2 methylation to differentiate dementia with Lewy bodies from Parkinson's disease.
|
31659741 |
2020 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Drd2 is also the primary target of both antipsychotics and Parkinson's disease medications.
|
30604007 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Results</b>: Adenosine A2A-dopamine D2 receptor (A2AR/D2R) heteromer formation was monitored in caudate from healthy and Parkinson's disease (PD) subjects.
|
31340557 |
2019 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to evaluate a possible relationship between DRD2/ANKK1 (rs1800497) and SLC6A3/DAT1 (rs28363170) gene polymorphisms with the response to levodopa (L-DOPA)-therapy in patients with Parkinson's disease (PD).
|
30353564 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
A dopamine D2 receptor agonist, pramipexole, has been found to elicit neuroprotection in patients with Parkinson's disease and restless leg syndrome.
|
31235613 |
2019 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The current meta-analysis suggested that a significant association between DRD2 TaqIA polymorphism and PD under the recessive genetic mode, and additive genetic models, especially in Caucasians.
|
31517853 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The D2 dopamine receptor (DRD2) is the primary target for both typical and atypical antipsychotic drugs, and for drugs used to treat Parkinson's disease.
|
29466326 |
2018 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
|
29434188 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the present study, we used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced PD mouse model to investigate whether Drd2 could suppress astrocytic NLRP3 inflammasome activation.
|
29786071 |
2018 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The poorer cognitive performance in DRD2 <sup>957</sup> T/T carriers with PD occurred mainly in episodic memory and attention.
|
28869277 |
2018 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To determine whether dopaminergic (rs1076560 DRD2 G > T and rs4680 catechole-o-methyltranspherase (COMT) Val158Met) or brain derived neurotrophic factor (rs6265 BDNF Val66Met) genetic polymorphisms are associated with gait function and medication responsiveness in Parkinson's disease.
|
29249680 |
2018 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
|
29908325 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our study illustrates that astrocytic Drd2 inhibits neuroinflammation through a β-arrestin2-dependent mechanism and provides a new strategy for treatment of PD.
|
30200997 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study aims to investigate how microRNA-200a (miR-200a) regulates striatal dopamine receptor D2 (DRD2) to affect apoptosis of striatum in rats with PD and to explore the associated mechanism.
|
30497067 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, we suggest that L-DOPA may attenuate the neuropathology of PD by regulating signaling related to DRD2 in neuronal cells under α-syn-induced toxicity.
|
28687316 |
2017 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To investigate the association between Dopamine receptor D type 2 (DRD2) dinucleotide short tandem repeat (CA<sub>n</sub>-STR) and Dopamine receptor D type 3 (DRD3) Ser9Gly polymorphisms and the risk of PD, as well as the possible reasons for PD patients using different doses of DAs, we recruited 168 idiopathic PD patients and 182 controls.
|
27817855 |
2017 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the topographical distribution of dopamine transporter (DAT), dopamine D2 receptor, and glucose metabolism in Parkinson's disease (PD) using PET/computed tomography (CT) scanning and statistical parametric mapping (SPM) analysis.
|
27893588 |
2017 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Human genetic studies also show a significant association of DRD2 polymorphisms with disorders including schizophrenia and Parkinson's disease.
|
29107444 |
2017 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The changes in expression at the mRNA and protein levels suggest that Snca may be involved in neurodegeneration and Drd2 may participate in the development of the compensatory mechanisms in the early stages of PD pathogenesis.
|
27757834 |
2017 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The DRD3 (rs6280) polymorphism, but not DRD2 (Taq1A) or GRIN2B, influences younger PD age of onset in the US Caucasian population.
|
26627941 |
2016 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms, rs2283265 and rs1076560, in the dopamine D2 receptor gene (DRD2) were found to be significantly associated with a favourable peak response to rasagiline at 12 weeks in early Parkinson's disease after controlling for multiple testing.
|
27190009 |
2016 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We examined the relation between inhibitory ability (measured by the Stop Signal Task) and polymorphisms of COMT Val158Met and DRD2 C957T in patients with idiopathic PD.
|
24749760 |
2014 |
|
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Pharmacological modulation of A2ARs is particularly useful in Parkinson's disease (PD) due to their property of antagonizing dopamine D2 receptor activity.
|
24892887 |
2014 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In the current study, we determined whether a dopamine D2 receptor DNA sequence polymorphism interacts with L-DOPA during motor tasks in patients with Parkinson's disease (PD).
|
23439215 |
2013 |